LIALDA PACKAGE INSERT PDF

LIALDA PACKAGE INSERT PDF

Check out Lialda for induction of remission in active mild to moderate UC and maintenance of UC remission. Read safety info including potential kidney. Shire US Manufacturing Inc.: LIALDA is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Lialda (mesalamine).

Author: Kagataur Goramar
Country: Uganda
Language: English (Spanish)
Genre: Video
Published (Last): 13 June 2004
Pages: 338
PDF File Size: 8.43 Mb
ePub File Size: 11.64 Mb
ISBN: 331-6-89531-120-6
Downloads: 48253
Price: Free* [*Free Regsitration Required]
Uploader: Samugis

E-mail this page or Web site to a friend or loved one by filling out the form below. Cookies are required to use some elements of this Web site. Click “Cancel” to return or “OK” to continue.

E-mail this page only. Talk to your doctor about why Lialda may be right for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Find information about UC. See Additional Important Safety Information. Our privacy policy does not apply to this site.

In clinical studies of Lialda, inflammation of the pancreas also occurred. Kidney problems have been reported with medications that contain mesalamine, such as Lialda.

The information contained in this section of the site is intended for US health care professionals only.

  EVERLASTING ANGIE FRAZIER PDF

This site is intended solely for US residents and is governed solely by US laws and government regulations. See Full Important Safety Information. E—mail this list of questions for the doctor — to yourself, a friend or a loved one — by filling out the form below. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

For the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for the maintenance of remission of UC.

All content lialfa this Web site, including text, images, graphics, sound files, and their arrangement, belongs to Shire and is protected by international copyright laws. Click OK if you are a health care professional.

If this happens to you, your doctor may tell you to stop taking Lialda. Your doctor may check to see how your kidneys are working before starting Lialda and periodically while taking Lialda. All other intellectual property rights are reserved. Lialda is a prescription medication approved for the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for the maintenance of remission of UC.

Ulcerative Colitis (UC) Treatment | Lialda® (mesalamine)

This link will take you to a Web site maintained by a third party, who is responsible for its content and privacy policy. Please review Shire’s Privacy Policy. Important Safety Information Do not take Lialda mesalamine if you are allergic to salicylates, such as aspirin, or medications that contain aspirin; aminosalicylates; mesalamine; or any other ingredients in Lialda.

  IPREMIER CASE STUDY PDF

You must have JavaScript enabled on your computer to access this Web site feature. You may need to adjust your Internet properties within your Web browser software, such as Microsoft Internet Explorer or Mozilla Firefox. All fields are required.

E-mail to a Friend

Do not take Lialda mesalamine if you are allergic to salicylates, such as aspirin, or medications that contain aspirin; aminosalicylates; mesalamine; or any other ingredients in Lialda.

We encourage you to read the privacy policy of every Web site you visit. Tell your doctor if you: Please see our privacy policy for more information. While Shire US Inc. Your e-mail address and that of the recipient will be used for transmission only and will not be used for any other purposes. Please see Full Prescribing Information for Lialda mesalamine.

Following Your Prescribed Treatment Plan. Shire does not control the content of non-Shire Web sites, and this link does not constitute an endorsement by Shire of the site’s content.